BIMI Holdings (BIMI) Fair Value & Analysis
Healthcare · US · Market cap $1.4K
BIMI Holdings
BIMI · US
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $1.30 to $0.0001 (−100.0%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $1.45 · the $0.0001 price screens below the $0.0001 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BIMI Holdings (BIMI) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, BIMI Holdings generated revenue of $12.6M at a net margin of -83.2%. Revenue declined 48.8% year over year. Net debt stands at $3.1M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
BIMI Holdings Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical solution, and pharmaceutical and other healthcare products in the People's Republic of China and the United States. The company operates through four segments: Medical Devices; Healthcare Products; Wholesale Pharmaceuticals; and Pharmacy Retail. The Pharmacy Retail segment offers prescription and OTC medicines; TCM; healthcare supplies; traditional Chinese medicines; and sundry items. The Wholesale Pharmaceuticals segment provides prescription; OTC medicines; TCM; healthcare supplies; and sundry items. The Medical Device segment distributes medical devices, including medical consumables. The Healthcare products segment offers dietary supplements comprising cardiovascular products; anti-insomnia and depression products; male aphrodisiac products; menopausal syndrome products; gout products; and immunity products. It sells its products through pharmacies; retail stores; …
Revenue & earnings trend
FY2019 – FY2023 · reported fiscal years
BIMI Holdings reported revenue of $12.6M in FY2023 versus $158K in FY2019, a compound +199.0%/yr. Reported net income was −$10.5M in FY2023.
Is BIMI fairly valued? → Check now
Similar stocks
6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIF | $5.85 | $7.13 | +22% |
| Alibaba Health Information Technology Limited ALBBY | $8.56 | $6.91 | -19% |
| Raia Drogasil S.A RADL3 | R$17.46 | R$16.13 | -8% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.91 | ¥22.00 | +5% |
| Clicks Group CLCGY | $27.97 | $34.29 | +23% |
| Sugi Holdings SGIPF | $16.29 | $32.19 | +98% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BIMI Holdings (BIMI) undervalued?
What is the fair value of BIMI?
What is the quality score of BIMI?
What is the revenue of BIMI Holdings (BIMI)?
What is the net profit margin of BIMI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.